Cargando…

A Discovery of Clinically Approved Formula FBRP for Repositioning to Treat HCC by Inhibiting PI3K/AKT/NF-κB Activation

Drug repositioning offers new clinical applications for existing drugs with shorter approval processes and lower costs and risks than de novo experimental drug development. The Fufang-Biejia-Ruangan pill (FBRP) is the first clinically approved anti-fibrosis herbal formula in China. Whether FBRP coul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yanqiong, Mao, Xia, Chen, Wenjia, Guo, Xiaodong, Yu, Liangxiang, Jiang, Funeng, Wang, Xiaoyue, Li, Weijie, Guo, Qiuyan, Li, Taixian, Lin, Na
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994416/ https://www.ncbi.nlm.nih.gov/pubmed/31982775 http://dx.doi.org/10.1016/j.omtn.2019.12.023

Ejemplares similares

Inferences of individual differences in response to tripterysium glycosides across patients with Rheumatoid arthritis using a novel ceRNA regulatory axis
por: Zhang, Yanqiong, et al.
Publicado: (2020)

Aberrant regulation of LncRNA TUG1-microRNA-328-3p-SRSF9 mRNA Axis in hepatocellular carcinoma: a promising target for prognosis and therapy
por: Liu, Yudong, et al.
Publicado: (2022)

Biomolecular network-based synergistic drug combination discovery: a combination of paeoniflorin and liquiritin alleviates neuropathic pain by inhibiting neuroinflammation via suppressing the chemokine signaling pathway
por: Guo, Qiuyan, et al.
Publicado: (2020)

Disease-Modifying Anti-rheumatic Drug Prescription Baihu-Guizhi Decoction Attenuates Rheumatoid Arthritis via Suppressing Toll-Like Receptor 4-mediated NLRP3 Inflammasome Activation
por: Li, Weijie, et al.
Publicado: (2021)

A novel gene-expression-signature-based model for prediction of response to Tripterysium glycosides tablet for rheumatoid arthritis patients
por: Zhang, Yanqiong, et al.
Publicado: (2018)

Thyroid hormone synthesis: a potential target of a Chinese herbal formula Haizao Yuhu Decoction acting on iodine-deficient goiter
por: Zhang, Yanqiong, et al.
Publicado: (2016)

Repurposing a clinically approved prescription Colquhounia root tablet to treat diabetic kidney disease via suppressing PI3K/AKT/NF-kB activation
por: Ma, Zhaochen, et al.
Publicado: (2022)

A Novel Circulating miRNA-Based Model Predicts the Response to Tripterysium Glycosides Tablets: Moving Toward Model-Based Precision Medicine in Rheumatoid Arthritis
por: Zhang, Yanqiong, et al.
Publicado: (2018)

Comprehensive analysis of microRNA-regulated protein interaction network reveals the tumor suppressive role of microRNA-149 in human hepatocellular carcinoma via targeting AKT-mTOR pathway
por: Zhang, Yanqiong, et al.
Publicado: (2014)

Larval Zebrafish Model for FDA-Approved Drug Repositioning for Tobacco Dependence Treatment
por: Cousin, Margot A., et al.
Publicado: (2014)

Repositioning approved drugs for the treatment of problematic cancers using a screening approach
por: Varbanov, Hristo P., et al.
Publicado: (2017)

In silico repositioning of approved drugs against Schistosoma mansoni energy metabolism targets
por: Calixto, Nicole Melo, et al.
Publicado: (2018)

Editorial: FDA-Approved Drug Repositioning for P-Glycoprotein Overexpressing Resistant Cancer
por: Yoon, Sungpil, et al.
Publicado: (2021)

Preclinical investigation of artesunate as a therapeutic agent for hepatocellular carcinoma via impairment of glucosylceramidase-mediated autophagic degradation
por: Chen, Wenjia, et al.
Publicado: (2022)

Identification of a novel microRNA-mRNA regulatory biomodule in human prostate cancer
por: Zhang, Yanqiong, et al.
Publicado: (2018)

Antiprotozoal Activity Profiling of Approved Drugs: A Starting Point toward Drug Repositioning
por: Kaiser, Marcel, et al.
Publicado: (2015)

Identification and assessment of novel dynamic biomarkers for monitoring non‐traumatic osteonecrosis of the femoral head staging
por: Jia, Yan, et al.
Publicado: (2023)

Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds
por: Carrella, Diego, et al.
Publicado: (2016)

A comprehensive approach to identify approved drugs and treatments for repositioning as therapies for systemic lupus erythematosus
por: Grammer, Amrie C, et al.
Publicado: (2014)

DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on patient survival information
por: Amelio, I, et al.
Publicado: (2014)

Targeting the AKT pathway: Repositioning HIV protease inhibitors as radiosensitizers
por: Goda, Jayant S., et al.
Publicado: (2016)

NF-Y Overexpression in Liver Hepatocellular Carcinoma (HCC)
por: Bezzecchi, Eugenia, et al.
Publicado: (2020)

Vascular endothelial cells facilitated HCC invasion and metastasis through the Akt and NF-κB pathways induced by paracrine cytokines
por: Wang, Yao-Hui, et al.
Publicado: (2013)

Qizhi Kebitong Formula Ameliorates Streptozocin-Induced Diabetic Osteoporosis through Regulating the PI3K/Akt/NF-κB Pathway
por: Tian, Lulu, et al.
Publicado: (2022)

Elevated Serum Uric Acid is Associated With Poor Survival in Advanced HCC Patients and Febuxostat Improves Prognosis in HCC Rats
por: Wu, Le, et al.
Publicado: (2021)

Juglanthraquinone C Induces Intracellular ROS Increase and Apoptosis by Activating the Akt/Foxo Signal Pathway in HCC Cells
por: Hou, Ya-Qin, et al.
Publicado: (2016)

Online structure-based screening of purchasable approved drugs and natural compounds: retrospective examples of drug repositioning on cancer targets
por: Lagarde, Nathalie, et al.
Publicado: (2018)

RNAi-based small molecule repositioning reveals clinically approved urea-based kinase inhibitors as broadly active antivirals
por: Lesch, Markus, et al.
Publicado: (2019)

Virtual screening and drug repositioning of FDA-approved drugs from the ZINC database to identify the potential hTERT inhibitors
por: Afzaal, Hasan, et al.
Publicado: (2022)

CDCA2 Promotes HCC Cells Development via AKT–mTOR Pathway
por: Li, Kai, et al.
Publicado: (2022)

Feasibility and Efficacy of S-Adenosyl-L-methionine in Patients with HBV-Related HCC with Different BCLC Stages
por: Guo, Tao, et al.
Publicado: (2016)

Preclinical efficacy of TZG in myofascial pain syndrome by impairing PI3K-RAC2 signaling-mediated neutrophil extracellular traps
por: Liu, Xueting, et al.
Publicado: (2023)

Repositioning of clinically approved drug Bazi Bushen capsule for treatment of Aizheimer's disease using network pharmacology approach and in vitro experimental validation
por: Wang, Tongxing, et al.
Publicado: (2023)

Pentosan polysulfate ameliorates fibrosis and inflammation markers in SV40 MES13 cells by suppressing activation of PI3K/AKT pathway via miR-446a-3p
por: Xiao, Liangxiang, et al.
Publicado: (2022)

Ex vivo and In vitro antiplasmodial activities of approved drugs predicted to have antimalarial activities using chemogenomics and drug repositioning approach
por: Ochora, Douglas O., et al.
Publicado: (2023)

Computational prognostic evaluation of Alzheimer’s drugs from FDA-approved database through structural conformational dynamics and drug repositioning approaches
por: Hassan, Mubashir, et al.
Publicado: (2023)

Drug repositioning in drug discovery of T2DM and repositioning potential of antidiabetic agents
por: Zhu, Sha, et al.
Publicado: (2022)

Puerarin 6″‐O‐xyloside suppressed HCC via regulating proliferation, stemness, and apoptosis with inhibited PI3K/AKT/mTOR
por: Li, Long, et al.
Publicado: (2020)

Integrative network fusion-based multi-omics study for biomarker identification and patient classification of rheumatoid arthritis
por: Ding, Zihe, et al.
Publicado: (2023)

Lip repositioning
por: Gaddale, Reetika, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_vbvi16dv42mqo4hb60968eq3i5